Glimepirid Teva (Glimepiride)

Glimepirid Teva is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic targets.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy in patients newly diagnosed with type 2 diabetes.
• May be combined with metformin or other oral antidiabetic agents when additional glucose lowering is needed.
• Suitable for adults who have adequate pancreatic beta‑cell function.
• Helps reduce HbA1c when taken consistently as part of a comprehensive diabetes management plan.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common

• Low blood sugar (hypoglycemia), especially when meals are skipped.
• Weight gain.
• Nausea or gastrointestinal discomfort.
• Headache.
• Dizziness.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, itching, or swelling.
• Blood cell abnormalities (e.g., leukopenia, thrombocytopenia).
• Liver function abnormalities.
• Cardiovascular events in patients with pre‑existing heart disease.

Before initiating Glimepirid Teva, healthcare providers should evaluate several clinical factors to minimize risks.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Verify that the patient has sufficient endogenous insulin production.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Review history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Monitor for signs of allergic reactions during the first weeks of therapy.
• Educate patients on recognizing and managing hypoglycemia.

Glimepirid Teva can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride plasma levels.
• High‑dose salicylates or NSAIDs that can potentiate hypoglycemic episodes.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect blood glucose control.
• Antidepressants such as SSRIs, which have been reported to influence glycemic balance.